Even if previous pharmacokinetic studies showed that Exendin-4 treatment with current dosing results in circulating levels between 2.5 and 5 nM,29 higher doses of GLP-1 analogues are now under consideration for weight management.2 AT samples were used from non-diabetic overweight/obese subjects who are typically insulin resistant, whereas GLP-1 treatment is primarily for subjects with type-2 diabetes. This evidence concerns the gene INS and type 2 diabetes mellitus.